EpiVario files Form D for $500,000 debt offering
The Philadelphia pharmaceutical company has sold $185,000 of a planned $500,000 note offering to nine investors as of October 13, 2026.
EpiVario Inc., a Delaware corporation based in Philadelphia, Pennsylvania, filed a Form D with the Securities and Exchange Commission dated October 13, 2026, disclosing an exempt securities offering. The filing is a new notice listing a date of first sale of September 25, 2026.1
The offering covers debt securities as well as options, warrants or other rights to acquire securities, and securities to be acquired upon exercise of such rights.1 The company claimed the Rule 506(b) exemption under Regulation D.1
The total offering amount is listed as $500,000, with $185,000 sold so far and $315,000 remaining to be sold.1 The minimum investment accepted from any outside investor is $25,000.1 Nine investors have already put money into the offering.1
The filing reports no sales commissions or finders' fees paid in connection with the offering.1 EpiVario estimated that $45,000 of the gross proceeds would go toward payments to executive officers, directors, or promoters named in the filing.1
The company selected "Decline to Disclose" for its revenue range or aggregate net asset value range.1 EpiVario indicated it does not intend for the offering to last more than one year.1
The filing names Thomas Kim as an executive officer and director, with Christopher Cashman and Eric Schultenover also listed as directors.1 Thomas Kim, identified as President and CEO, signed the notice on October 13, 2026.1 The company classified its industry as pharmaceuticals under the health care sector.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.